Alignment Healthcare, Inc.
Alignment Healthcare (ALHC) reported Q2 2026 revenue of $1.34B and net income of $36.56M, with diluted EPS of $0.17. For the first half, net income rose to $47.98M. The company raised full-year 2026 revenue guidance to $5.20B to $5.23B, citing continued momentum, while noting Medicare Advantage regulatory and reimbursement risks.
Kaplan Fox & Kilsheimer LLP said it is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) after a July 8, 2026 whistleblower complaint alleged accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the news, ALHC shares fell $4.02, or 16.7%, to close at $20.03.
Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.
Over the past 7 days, alphai's AI scored 7 news stories mentioning ALHC (Alignment Healthcare, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 4 bearish.
Recent ALHC coverage spans financial news, earnings and regulation.
In the last 30 days, ALHC insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($9.6M). The most active reporter was KAO JOHN E, Chief Executive Officer, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The guidance raise supports the near-term execution narrative, but the article flags Medicare Advantage reimbursement rule-change risk as the main margin overhang.
The article centers on a securities-law investigation solicitation tied to alleged financial misclassification, which can raise litigation and credibility risk for ALHC.
Guidance upside is partially offset by a planned profitability step-down in Q3 from accelerated clinical, AI, and expansion spending.
Near-term risk is margin pressure from higher-acuity mix and heavier second-half spending, partially offset by improved medical-cost control and cash generation.
The article spotlights potential financial reporting misconduct, which typically raises downside risk via restatement, regulatory scrutiny, and litigation overhang.
alphai scores every news story that mentions ALHC with an AI model for sentiment and relevance, and aggregates insider trades from Alignment Healthcare, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alignment Healthcare (ALHC) reported Q2 2026 revenue of $1.34B and net income of $36.56M, with diluted EPS of $0.17. For the first half, net income rose to $47.98M. The company raised full-year 2026 revenue guidance to $5.20B to $5.23B, citing continued momentum, while noting Medicare Advantage regulatory and reimbursement risks.
5 min readKaplan Fox & Kilsheimer LLP said it is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) after a July 8, 2026 whistleblower complaint alleged accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the news, ALHC shares fell $4.02, or 16.7%, to close at $20.03.
4 min readAlignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.
6 min readAlignment Healthcare (ALHC) reported Q2 2026 membership up 31.5% to about 294,100 and revenue up 31.6% to $1.34 billion. Adjusted gross profit rose 35.3% to $182.9 million and adjusted EBITDA rose 48.4% to $68.1 million. Management raised full-year 2026 outlook to 298,000-301,000 members and $5.20-$5.23 billion revenue, while valuation remains mixed versus peers.
7 min readKaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.
3 min readGlancy Prongay Wolke & Rotter LLP said it is continuing an investigation for Alignment Healthcare, Inc. (NASDAQ: ALHC) investors after a whistleblower lawsuit alleged financial manipulation. The suit claims Alignment misclassified $8 million to $10 million of operating expenses as capital expenditures to boost adjusted EBITDA and executive pay. Alignment shares fell about 16.7% on July 8, 2026, to $20.03.
2 min readAlignment Healthcare Inc. (NASDAQ: ALHC) shares fell about 18.66% amid whistleblower-driven accounting investigation and related legal scrutiny tied to Medicare Advantage reimbursement and alleged misclassification of expenses. The article cites Q2 2026 revenue around $1.34B, net income about $36.56M, diluted EPS about $0.17, and valuation near 106x trailing EPS.
6 min readAlignment Healthcare (ALHC) shares fell 14.8% after the company said it will reinvest profits, lowering expected second-half 2026 earnings. On its Q2 2026 call, management raised full-year revenue guidance but expects only about 30% of adjusted EBITDA in the second half, versus 40% a year earlier, due to investment timing.
3 min readThursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - John E. Kao Chief Financial Officer - James Head TAKEAWAYS Health Plan Membership -- 294,000 members, representing 31% growth year over year. Total Revenue -- $1.3 billion, an increase of 32% year over year driven by membership growth. Adjusted MBR -- 86.3%, an improvement of 40 basis points year over year and the lowest since the company went public.
6 min readStock falls 12% in after-hours trading Shares in Alignment Healthcare fell 12% in after-hours trading after reporting second quarter results. Orange-based Alignment, a Medicare Advantage provider for seniors, reported earnings per share (EPS) of 17 cents, missing the 20-cent consensus estimate, according to the TheFly.com. The company’s third-quarter revenue outlook of $1.3 billion to $1.32 billion also came in at the low end of Wall Street estimates.
2 min read
